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EVIDENCE-BASED PRACTICE:
From Concepts to Reality
LINDA GOWING
A great and increasing challenge facing all practitioners, regardless of their
discipline or background, is how to keep abreast of new research findings.
This is particularly relevant in the AOD field as there have been substantial
expansions in our scientific knowledge base over the past 10 to 20 years.
There is growing pressure on the AOD workforce to function from an
evidence-based perspective.  This paper examines the basic concepts of
evidence-based practice and some of the basic tools and techniques
involved.
ll clinicians would like to think that they are following best
practice and that their practice is based on evidence.
However, evidence-based practice means more than practicing
with an awareness of research evidence.  A widely accepted definition
of evidence-based medicine is a “conscientious, explicit and judicious
use of current best evidence in making decisions about individual
patients” (Sackett et al, 1996).  This is reflected in Figure 1, which
depicts clinical decisions taking account of research evidence, clinical
expertise and patient preference (Haynes et al, 1996).
Figure 1: A Model for Evidence-Based Clinical Decisions
The concept of evidence-based practice is also applicable at a broader
level of health care decision making.
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Silagy and Haines (1998) describe evidence-based health care as an approach that “takes account
of evidence at a population level as well as encompassing interventions concerned with the
organisation and delivery of health care”.  This is reflected in Figure 2, which shows different
types of evidence on the effects of care feeding into policies and health care decisions.
The consistent point with these models of clinical decisions and health care is that research
evidence is a component of the decision-making process, but it is not the only component.  Other
aspects (clinical expertise, patient preference, needs, priorities and resources) are also important
considerations.  Nonetheless the models demonstrate that, if we are to achieve evidence-based
practice, we need to incorporate research evidence into decisions.
Figure 2: Evidence-Based Practice in Health Care
WHAT IS EVIDENCE?
The concept of incorporating research evidence into decisions seems simple, but complexities arise
as soon as you start to consider what is meant by “research evidence”.  The above definition of
evidence-based medicine refers to “judicious use of current best evidence”.  This raises questions
of what is “current” and “best”, how do we find it, and what sort of judgements need to be applied
in using it “judiciously”.
Then there is the sheer scale of research literature.  It is estimated that there are 3,000 new medical
articles published every day.  Of these, 1,000 will be included in Medline and 46 will be
randomised controlled trials.  Furthermore, the volume of information has been steadily increasing.
For example, in 1976 Medline contained 3,810 articles on hypertension, in 1996 there were 7,591.
Clearly it is impossible for any one person, or even a small team of people, to monitor this volume
of literature, let alone use it “judiciously”.
This situation of information overload necessitates strategies that make good quality research
evidence readily available.  Hence promoting evidence-based practice entails:
• location of evidence
• critical appraisal
• synthesis of findings
• dissemination.
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This paper focuses on two aspects - critical appraisal and synthesis of findings.  Research on
interventions for the management of opioid withdrawal will be used as an example to consider how
the implementation of evidence-based practice can be limited by the realities of available research.
CRITICAL APPRAISAL
If we are to identify “best” evidence and use it judiciously, we must critically appraise the
evidence, and not simply accept it on face value.  Critical appraisal means considering research in
terms of:
• quality (the methods used to minimise bias in a study design)
• relevance (the outcome measures used and the applicability of study results to other
treatments, settings and patients)
• strength (the magnitude, precision and reproducibility of the intervention effect).
Levels of evidence (see Box 1 below) provide some indication of the degree to which bias has been
eliminated by study design (NHMRC, 1999) but levels of evidence place a particular emphasis on
whether participants were allocated randomly to study groups.  While randomisation is an
important measure for controlling bias, it addresses only one type of bias, namely selection bias.
Studies may be exposed to:
• selection bias (systematic differences in comparison
groups)
• performance bias (systematic differences in care provided
apart from the intervention being evaluated)
• attrition bias (differences in withdrawals from the trial)
• detection bias (systematic differences in outcome
assessment).
Critical appraisal needs to consider the extent to which all of
these sources of bias have been controlled for in the design and
conduct of research studies.  This means considering the use of
random allocation (control of selection bias), blinding or
masking of study participants and observers (control of
detection bias) as well as assessing the way in which the study
was carried out.  It is also worth noting that there is currently
vigorous debate about the emphasis that is placed on
randomised controlled trials, and whether this emphasis is
unreasonably detrimental to approaches such as comparative
cohort studies and longitudinal studies which may be a more
appropriate approach for investigating particular research
questions.  Interest in the use of alternative study designs is
particularly marked in areas in which there are social and
psychological dimensions to be considered in addition to
clinical aspects of treatment, such as alcohol and other drug
dependence.
SYNTHESISING RESEARCH EVIDENCE
The development of the techniques of systematic reviews and meta-analysis has arisen from the
need to summarise large amounts of research information concisely and accurately.
Box 1
Levels of Evidence
I Systematic review of RCTs
II At least one properly
designed RCT
III-1 Well-designed pseudo-
RCTs
III-2 Comparative (non-
randomised) studies with
concurrent controls, case-
control studies or
interrupted time series with
control group
III-3 Comparative studies with
historical control, two or
more single-arm studies or
interrupted time series
without parallel control
group
IV Case series, either post-
test or pre-test and post-
test
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The strengths of systematic reviews are that they:
• use scientific strategies to limit bias
• summarise the accumulated state of knowledge
• highlight important unresolved issues
• gain power from combining multiple studies
• address questions in a timeframe not achievable through
single studies
• quantify outcomes.
The systematic review process entails:
• precise formulation of the objective
• study retrieval and selection
• inclusion/exclusion criteria
• assessment of methodologic quality
• assessment of combinability
• data extraction
• analysis.
It is important to note that the review objective and the inclusion/exclusion criteria should be
defined before searching for research evidence.  This ensures objectivity in the preparation of
systematic reviews, with studies being assessed on the basis of set criteria and not subjective
judgements of what is “good” or “useful”.  Defining the review criteria before searching the
literature means that it is possible that no literature will be found.  This in itself is a useful finding
if the objective of the systematic review has been defined on the basis of perceived clinical need or
policy importance, as it identifies a significant gap in research.
The preparation of systematic reviews is a time-consuming process and is not something that
everyone will want to embark upon.  However, as with any form of evidence, it is important that
you critically appraise systematic reviews before using the findings.  To assess the quality of a
systematic review you should consider:
• is it a review of randomised trials of the treatment you are interested in?
• does it include a methods section that describes how all the relevant trials were found?
• did the authors assess the trials’ individual validity?
• were the results consistent from study to study?
THE COCHRANE COLLABORATION
The Cochrane Collaboration was established for the purpose of “preparing, maintaining and
disseminating systematic reviews of the effects of health care”.  It was inspired by an English
epidemiologist, Archie Cochrane:
“It is surely a great criticism of our profession that we have not organised a critical
summary, by specialty or sub-specialty, adapted periodically, of all relevant randomized
controlled trials.”
The work of the Cochrane Collaboration is undertaken through around 50 Collaborative Review
Groups, supported by Cochrane Centres around the world (the Australasian Cochrane Centre is in
Melbourne).  For more information see http://www.cochrane.org.
Box 2
Definitions
• Systematic review - the
application of scientific
strategies that limit bias to
the systematic assembly,
critical appraisal, and
synthesis of all relevant
studies on a specific topic
• Meta-analysis - a
systematic review that
employs statistical
methods to combine and
summarise the results.
LINDA GOWING
81
SEC
TIO
N
 3: Translating Research into Practice
The Drug and Alcohol Services Council, South Australia is associated with the Cochrane Drugs
and Alcohol Group.  The scope of this group is active interventions (prevention, treatment,
rehabilitation) aimed at reducing the potential for harm or the actual harm directly related to the use
of different dependence producing substances.  Tobacco is excluded as this is covered by a separate
collaborative review group.  The coordinator of the Cochrane Drugs and Alcohol Group is based at
the Agenzia di Sanita Pubblica Regione Lazio, Rome, Italy.
THE GOAL OF META-ANALYSIS
The power of a systematic review with meta-analysis is illustrated in the Cochrane review of
nicotine replacement therapy (Silagy et al, 1998).  A major outcome considered by the review,
namely abstinence from smoking after at least six months of follow-up, is detailed in Box 3 below.
The data combine the results of 88 separate trials.  Meta-analysis enables this data to be condensed
into a simple tabulation of outcomes for the different types of nicotine replacement therapy, and for
any type of nicotine replacement therapy compared to placebo or no treatment.
However, meta-analysis is only valid where:
• the primary literature is of good quality (ie
there is low risk of bias)
• heterogeneity in the response to treatment of
the tested population is small and well
understood
• interest centres on estimation of a specific,
critical parameter of outcome (Bailar, 1995).
In the above meta-analysis of nicotine replacement
therapy, these conditions are met by:
• limiting the review to randomised controlled trials that compared nicotine replacement
therapy with placebo or no treatment, or different doses of nicotine replacement therapy
• undertaking subgroup analyses to explore heterogeneity (the effect of setting, intensity of
additional support and the severity of dependence)
• defining the major outcome as abstinence of smoking after at least six months follow up with
biochemically validated rates wherever possible.
OPIOID WITHDRAWAL LITERATURE: A CASE ILLUSTRATION OF EVIDENCE-BASED PRACTICE
The meta-analysis from the Cochrane review of nicotine replacement therapy prepared by Silagy et
al (1998) is the sort of outcome that we would have liked to achieve for the management of opioid
withdrawal.  However, in attempting to achieve this goal, we encountered a range of limitations.
These are discussed in this section, on the basis of the three aspects of meta-analysis validity
identified above.
Study Quality
Systematic searching of the research literature resulted in the identification of a total of 716
references relating to opioid dependence and withdrawal.  Of these:
• 110 were randomised controlled trials
• 54 were non-randomised controlled trials
• four were crossover studies.
Box 3
Nicotine Replacement Therapy (NRT) for
Smoking Cessation
Odds ratios (95% CI) for abstinence with NRT
compared to control
• gum 1.63 (1.49 – 1.79)
• patches 1.73 (1.56 – 1.93)
• nasal spray 2.27 (1.61 – 3.20)
• inhaled nicotine 2.08 (1.43 – 3.04)
• sublingual tablet 1.73 (1.07 – 2.80)
• all NRT 1.71 (1.6 – 1.8)
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Hence, controlled studies (of all types of intervention) constitute less than one quarter of the
research literature.  Furthermore, studies generally used small group sizes meaning they were also
exposed to random error.
Sources of Heterogeneity
1. Treatment Regimens
There is considerable diversity in the type of treatment regimens used to manage opioid
withdrawal.  The use of placebo or no-treatment comparisons is rare, and probably unethical - in
the absence of active treatment, opioid dependent people undergoing withdrawal rapidly develop
marked symptoms, become distressed and either drop-out or are transferred to active treatment.
Either way, the use of placebo or no-treatment comparisons is untenable, meaning that most studies
now compare different active treatment regimens.  This in itself is not problematic except that the
diversity of treatment regimens extends to both experimental and control arms of studies.  Adjunct
treatments (pharmacological and psychosocial) are also variable and often not documented in
detail.  This diversity in approach complicates attempts to combine the findings of multiple studies.
The main types of treatment regimen used for the management of opioid withdrawal are:
• reducing doses of opioid agonist (usually methadone)
• symptom amelioration with α2-adrenergic agonists (mainly clonidine, but with increasing
use of lofexidine)
• induction of withdrawal with opioid antagonists (naloxone or naltrexone), sometimes in
conjunction with heavy sedation or anaesthesia
• symptom amelioration with buprenorphine.
These approaches formed the basis for the preparation of four Cochrane reviews on the
management of opioid withdrawal.
2. Treatment Setting
There are no studies that compare identical
treatment regimens delivered in inpatient and
outpatient settings.  Therefore, to gain some idea of
the impact of setting we combined data from all
studies (including single group studies) where
groups of participants were treated entirely in
either an inpatient or an outpatient setting, using
either reducing doses of methadone, or clonidine to
manage withdrawal.  This produced the data shown
in Box 4.  Because of the method used to calculate
the completion rates, the data is subject to bias,
making the accuracy of the calculated rates
uncertain.
Nonetheless it indicates that rates of completion of withdrawal are consistently higher when
withdrawal occurs in an inpatient, compared to an outpatient, setting.  Hence the treatment setting
is a source of heterogeneity that needs to be considered when combining the findings of multiple
studies.  However, there are insufficient follow-up data available to form a view on how long the
advantage offered by inpatient treatment is maintained.
Box 4
Effect of Treatment Setting on
Completion of Withdrawal
Completion Rate
Regimen Inpatient Outpatient
Methadone 78% 31%
(n=740) (n=1,144)
Clonidine 70% 52%
(n=663) (n=842)
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3. Drug of Dependence
There are very few studies that compare withdrawal according to the main drug from which
participants are withdrawing.  Consequently, the data shown in Box 5 are again derived by
combining data from all studies where there were participants identified as withdrawing from either
heroin or methadone, with withdrawal managed with either reducing doses of methadone or an α2-
adrenergic agonist (usually clonidine or lofexidine).  As with the analysis of the impact of
treatment setting, these data are also subject to bias making the accuracy of the calculated
completion rates uncertain.  However, these data again indicate that the nature of the drug from
which participants are withdrawing affects the rate of completion of withdrawal and is another
source of heterogeneity to be considered in any meta-analysis.
The data indicate that completion of withdrawal is
somewhat more likely for people withdrawing
from methadone, compared to heroin.  This is
despite evidence that withdrawal from methadone
is more severe and more prolonged than
withdrawal from heroin.  This would be expected
to reduce, not increase, the likelihood of
completion of withdrawal.
People withdrawing from methadone may have
been obtaining methadone illicitly, have been
prescribed methadone for a short period of time (a
few days to a few weeks) in preparation for
detoxification, or they may have been receiving
methadone maintenance treatment.
Participation in methadone maintenance treatment would be expected to help people to stabilise in
health and social terms and hence to be better prepared for withdrawal.  It seems likely that it is the
impact of methadone maintenance treatment that is resulting in the higher rates of completion for
withdrawal from methadone, compared to withdrawal from heroin.  It would be of interest to
confirm whether this is the case, but there are insufficient data available to investigate this issue
further.
Outcome Indicators
1. Completion of Withdrawal
Withdrawal occurs when the drug of dependence is eliminated from the body, and any physical
adaptation that has occurred as a consequence of dependent drug use is reversed.  Detoxification
entails the provision of interventions to ensure that withdrawal can be completed with safety and
comfort.
Because detoxification addresses only the physical adaptation, and not the social dimensions of
dependence, detoxification is not in itself a treatment for dependence (Lipton and Maranda, 1983;
Mattick and Hall, 1996).  Rather, detoxification is generally regarded as a necessary stepping stone
to drug-free treatment.  Given this, it is questionable whether completion of withdrawal constitutes
a specific, critical parameter of outcome.  Indeed, it could be argued, on the basis of detoxification
being a stepping stone to treatment, that a more appropriate outcome indicator would be
engagement and retention in further treatment.  However, engagement and retention in further
treatment is very rarely used as an outcome indicator.  Of the studies we assessed, 78% included no
information on post-detoxification outcomes.  Only 3% had some information on the nature of
post-detoxification treatment and 18% included information on drug use at follow-up (most
Box 5
Effect of Drug of Dependence on
Completion of Withdrawal
Completion Rate
Regimen Heroin Methadone
Methadone 36% 55%
(n=578) (n=563)
Adrenergic 58% 73%
agonist (n=572) (n=410)
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commonly one month after detoxification).  Consequently we were forced to accept completion of
withdrawal as a significant parameter of outcome.
Assessing completion of withdrawal is also problematic.  The definition of completion varied
between studies (see Box 6) with the result that differences between studies can often, in part, be
attributed to differing definitions.  The best indicator of completion would be a combination of
subsidence of withdrawal signs and symptoms and objective confirmation that drug use has ceased.
As this was rarely possible we were forced to accept whatever was stated by authors as the number
of study participants who had completed withdrawal.
2. Severity and Adverse Effects
The stated aim of detoxification services is
generally to ensure that withdrawal can be
completed in safety and comfort.  Hence
withdrawal severity and the occurrence of adverse
events are important outcomes to consider when
comparing different approaches to the management
of opioid withdrawal.
There was huge diversity in methods of assessment
and reporting of withdrawal severity.  We
identified more than 70 different rating scales for
the 151 references that used at least one.  This
diversity complicated the comparison of findings
from different studies, and generally made meta-
analysis of withdrawal severity impossible.
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